Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | RBP4 | P02753 | 1/20 | 0.53 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | RARA | P10276 | 7/20 | 0.48 |
| ▸ | RARB | P10826 | 7/20 | 0.48 |
| ▸ | RARG | P13631 | 6/20 | 0.48 |
| ▸ | RXRA | P19793 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | RXRB | P28702 | 2/20 | 0.48 |
| ▸ | RXRG | P48443 | 2/20 | 0.48 |
| ▸ | RORC | P51449 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958099 | 1.00 | CYP1A2 (0.59) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL955099 | 0.97 | CYP1A2 (0.57) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL955100 | 0.97 | CYP1A2 (0.57) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL958447 | 0.90 | CYP1A2 (0.57) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL958445 | 0.90 | CYP1A2 (0.57) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL21088437 | 0.89 | CYP1A2 (0.66) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL958562 | 0.88 | CYP1A2 (0.61) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL955001 | 0.88 | CYP1A2 (0.61) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL958357 | 0.88 | CYP1A2 (0.65) | CYP1A2RBP4HAO1ALDH1A1RARA | |
| SCHEMBL955002 | 0.88 | CYP1A2 (0.61) | CYP1A2RBP4HAO1ALDH1A1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | claimed |
| EP-2442644-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2016-08-10 | — | — | EP | claimed |
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3100723-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2442644-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010147653-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, UACA | CYP1A2 4582/4885RBP4 25/4885HAO1 3585/4885 |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | CYP1A2 4582/4885RBP4 25/4885HAO1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.